Study of PVS-10200 for the Treatment of Restenosis in Patients With Peripheral Artery Disease (TRIUMPH)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2012-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the safety of two doses of PVS-10200, an allogeneic cellular therapy, delivered as a single injection following percutaneous transluminal ("balloon") angioplasty and stent placement for the treatment of peripheral artery disease (PAD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

NCT04848220

Microvascular Obstruction

TERMINATED PHASE2

Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

NCT02956993

Peripheral Artery Disease

COMPLETED PHASE1

SDF1 Plasmid Treatment for Patients With Peripheral Artery Disease

NCT02544204

Peripheral Arterial Disease

UNKNOWN PHASE2

Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstructive Coronary Artery Disease (IMPROVE-Ischemia)

NCT04826172

Ischemia Coronary Artery Disease

COMPLETED PHASE2

Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease

NCT01157156

Peripheral Arterial Occlusive Disease

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an open-label dose escalation safety study of PVS-10200 in 30 subjects with peripheral artery disease (PAD) requiring balloon angioplasty and stent placement in the superficial femoral artery (SFA). The study will be completed sequentially in two dose cohorts of 10 subjects (low dose group, Cohort A) and 20 subjects (high dose group, Cohort B). A Data Safety Monitoring Board (DSMB) will conduct regular safety reviews.

Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection to the perivascular region (external to the vessel) of the stented target lesion. The treatment will be administered within 24 hours after balloon angioplasty/stent placement.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peripheral Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PVS-10200

Each subject will receive one treatment of PVS-10200 delivered by ultrasound guided injection perivascular to the region of the target lesion within 24 hours of the completed angioplasty and stent placement.

Group Type OTHER

PVS-10200

Intervention Type BIOLOGICAL

PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PVS-10200

PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject has signed the informed consent document and patient information leaflet.
2. Male and female subject ≥ 18 years of age at the time of consent.
3. If female, the subject is (a) at least 1 year post-menopausal, or (b) surgically sterile, or (c) of child-bearing potential, with a negative serum pregnancy test result prior to study enrollment, who agrees to use adequate contraception for 6 months. Adequate contraception is defined as abstinence or a reliable method of birth control (e.g., a hormonal contraceptive, intra-uterine device, implantable or injectable contraceptives (Norplant® or Depo-Provera®), diaphragm, or condom with spermicide).
4. Subject has symptomatic peripheral arterial disease involving the superficial femoral artery, defined as Fontaine Class IIb, III and IV.
5. Meets anatomic requirements based on biplane digital subtraction angiography performed at the time of intervention including:

* Stenosis of ≥ 50% or occlusion of the superficial femoral artery, and
* Target lesion length of ≤ 150 mm, and
* At least one patent (\< 50 % stenosis) tibioperoneal runoff vessel
6. Target lesion is 7-15 cm in length.
7. Subject is expected to stay in the same geographic area for at least 48 weeks.
8. In the opinion of the investigator, the subject is able to understand and is willing to complete the study requirements.
9. Subject is receiving a therapeutic dose of statin therapy (starting minimum of 7 days prior to intervention) and continuing for a minimum of 4 weeks post-intervention.

Exclusion Criteria

1. Subject has acute limb ischemia.
2. Subject has had prior revascularization of the target lesion.
3. Subject has untreated inflow disease of the ipsilateral pelvic arteries (\> 50% stenosis or occlusion).
4. The target lesion is located within an aneurysm or associated with an aneurysm in the vessel segment either proximal or distal to the target lesion(s).
5. Subject has an unresolved thrombus within the target vessel.
6. Additional percutaneous interventional procedures (cardiac/peripheral) are planned ≤ 30 days following the study procedure.
7. Subject has suffered a hemorrhagic stroke ≤ 6 mo prior to the study procedure.
8. Subject has a history of bleeding diatheses or coagulopathy.
9. Subject is diagnosed with septicemia at the time of the study procedure.
10. Subject is known to be seropositive for HIV.
11. Subject has some other medical illness that may cause the subject to be non-compliant with the protocol.
12. Subject has a known allergy to bovine or porcine products (i.e., heparin).
13. Subject has a known allergy to collagen/gelatin products.
14. Subject has had a severe reaction to contrast media.
15. Subject has a known allergy or intolerance to anti-platelet medication (e.g., acetylsalicylic acid or clopidogrel) or statin therapy.
16. Subject has a history of IV drug use within 6 months prior to screening.
17. Subject has a documented diagnosis of cancer within 2 years (24 months) prior to screening.
18. Subject is a female who is pregnant, breast-feeding, or plans to become pregnant during the study.
19. Subject is currently participating in another investigational drug, biologic or device trial, plans to participate in another investigational drug, biologic or device study during participation in this study, or has completed participation in another investigational drug, biologic or device trial within the last 30 days. Note: Subjects involved in extended follow-up trials for products that are currently commercially available and used as approved are not considered to be participating investigational trials.
20. Subject is a staff member of any of the participating institutions or relative of a staff member.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No